Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protalix CEO confident data submission will address US FDA concerns for Gaucher's drug

This article was originally published in Scrip

Executive Summary

Investors felt somewhat reassured that Protalix BioTherapeutics had satisfactorily dealt with requests for additional data outlined by US regulators in a February complete response letter (CRL) for the Carmiel, Israel-based firm's investigational Gaucher's disease drug taliglucerase alfa, giving the company's shares a 3.6% boost on 1 August in US trading, or 23 cents, before closing at $6.64, a gain of 20 cents, or 3.1%.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts